GlassScriptPhysician profile
Veronica M Patterson
NPI 1962408997
$6,764.16
in general payments reported to CMS, 2019-2025
36 companies · $961 in 2025
The $961 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $782 · 2021: $955 · 2022: $1,067 · 2023: $1,121 · 2024: $765 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,827 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,827.15 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,691.50 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $852.45 | 2021-2025 | |
| Lilly USA, LLC | $432.67 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Otsuka America Pharmaceutical, INC. | $398.97 | 2019-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $320.90 | 2021-2025 | |
| Amgen INC. | $231.66 | 2019-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $228.47 | 2019-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.46 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $180.05 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $173.13 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $125.41 | 2019-2022 | |
| Mylan Specialty L.P. | $124.79 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $87.84 | 2019-2022 | |
| Pfizer INC. | $77.33 | 2019-2025 | |
| Lundbeck LLC | $69.93 | 2022-2025 | Rexulti |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.